REMEDi4ALL

Drug Repositioning and Repurposing Conference
2022-11-14 - 2022-11-15 | Westin Arlington Gateway, 801 North Glebe Road, Arlington, VA, 22203, United States
Join us at the 10TH ANNUAL DRUG REPOSITIONING AND REPURPOSING CONFERENCE, where attendees will meet and learn from the world’s foremost experts in the fields of repositioning and repurposing. As the Single Longest-Running Conference in the Space, Arrowhead Publishers’ annual event continues to be the “go to” meeting for pharma executives, academicians, researchers and patient advocacy groups who want to keep abreast of new developments in the field, learn from experts and meet possible collaborators and partners.
Key Subjects Covered at This Event
Patient Advocacy Efforts
Emphasis on and engagement with patient advocacy groups, who are investing in drug repositioning efforts to an unprecedented degree.
New Partnerships
The conference will explore how new partnerships between various groups, including government, industry and academia are advancing repurposing.
Systematic Repositioning & Data Analytics
Repurposing is no longer based on serendipity as more and more companies are designing tools to streamline and increase the odds of success.
Cutting-Edge Technologies
Artificial intelligence and other technologies are quickly reshaping drug discovery and development. This event will showcase how they are reshaping the field of drug repurposing.
Regulatory and Legal Guidance
Legal, IP and regulatory guidance will be shared with the audience, including knowlege and insight into the 505(b)(2) regulatory pathway.
Key Therapeutic Areas for Repurposing
Repurposing is beginning to make its mark in a range of therapeutic areas in need of new therapies. Rare and orphan diseases, tropical diseases and cancer will be discussed in terms of repurposing efforts currently underway.

Advanced Course in Network Medicine
2022-10-19 12:00 - 2022-10-20 12:30 (Europe/Amsterdam) | Campus Flemingsberg & Online
KI NMA is proud to invite you to participate in an advanced course in Network medicine – “From byte to bench to bed side – addressing large and complex data sets in biomedicine”.

The advanced course in network medicine “From byte to bench to bed side – addressing large and complex data sets in biomedicine” will be held both at Neo (Campus Flemingsberg) and streamed online.

The course is aimed towards PhD students, postdocs, researchers and everyone else that wants to learn more about the topic of network medicine, its application and implementation.
The course will start with a key note speaker, Professor Ed Silverman, Channing Division of Network Medicine, Brigham and Wome’s Hopital/Harvard Medical School, and the following session of the course will see lecture given by distinguished scientist from Europe and Sweden. The sessions will be followed by panel debates on the pros and cons, and the innovative potential of Network Medicine.
Updated program. Registration is now closed.

Drug Repurposing for Rare Diseases 2022
2022-10-10 09:00 - 18:00 (Europe/London) | America Square Conference Centre, 17, One Crosswall, America Square, Londen, EC3N 2LB, United Kingdom
We are delighted to announce our ninth annual Drug Repurposing for Rare Diseases Conference and, for the first time since 2020, it’s returning live and in-person!
Our annual conference, Drug Repurposing for Rare Diseases, highlights the role that drug repurposing can play in lowering the cost and accelerating the development of rare disease treatments.
An event unique in its collaborative and multi-stakeholder focus, we bring patient groups, researchers and industry professionals together to showcase excellent examples of rare repurposing.
Drug Repurposing for Rare Diseases sparks cross-sector conversation, uniting the expertise of diverse groups to inspire meaningful, patient-centred drug repurposing research for rare diseases.

CeBIL Annual Symposium 2022 - Intellectual Property and Drug Repurposing: New Frontiers
2022-09-16 00:00 - 18:00 (Europe/London) | Newnham College, University of Cambridge, Sidgwick Avenue, Cambridge, CB3 9DF, United Kingdom
Repurposing, the idea of finding new treatments for already authorised drugs, presents significant advantages for drug development. Modern drug development is hindered by high costs and research that takes over a decade.
Repurposing is a potential solution to these problems because it is cheaper, faster and safer than developing new compounds. However, academics, policymakers and industry experts argue that repurposing is underutilised, pointing at gaps in patent and pharmaceutical law that make it financially unviable.
The symposium will focus on important policy issues for pharmaceutical repurposing. In particular, it will examine new empirical data on patent protection, regulatory exclusivities and market authorisation pathways. It will also discuss two new public sector repurposing initiatives launched in the UK and EU, and investigate other policy frontiers. It will have a hybrid format, with both in-person and online only tickets available.
The 2022 CeBIL Symposium is organised by the Cambridge Centre for Law, Medicine and Life Sciences (LML) in combination with the Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) at the University of Copenhagen. The Symposium is generously supported by the Novo Nordisk Foundation.
Hosted by the University of Cambridge, an international hub for legal and scientific expertise, we hope the event will stimulate discussion between legal, economic,business, medical, and scientific experts at a range of career stages.
Confirmed participants include:

Prof. Timo Minssen (CeBIL, University of Copenhagen)
Prof. Kathleen Liddell (LML, University of Cambridge)
Prof. Mateo Aboy (LML, University of Cambridge)
Dr Jakob Wested (CeBIL, University of Copenhagen & Danish Medicines Agency)
Ms Eugenia Wachters (Healx)
Dr Anita Marguerie de Rotrou (Office for Translational Research, University of Cambridge)
Mr Adrian Freeman (AstraZeneca)
Professor Ken Shadlen (London School of Economics)
Dr John Liddicoat (LML, University of Cambridge)
Dr Rosemary Lovett (Medicines Repurposing Programme, NHS England)
Dr Charlotte Asker-Hagelberg (Swedish Medical Products Agency)
Dr Julian Huppert (Intellectual Forum, Jesus College, University of Cambridge)
Dr Marco Schito (Critical Path Institute)
Mr Paul Fleming (British Generic Manufacturers Association)
Ms Jacqueline Mulryne (Arnold & Porter)
Prof. Sir Munir Pirmohamed (NHS Chair of Pharmacogenetics & University of Liverpool)

The CeBIL Symposium will coincide with the EPIP Annual Conference in Cambridge (14-16 September 2022).

REXPO22 – 1st international conference on drug repurposing
2022-09-02 08:00 - 2022-09-03 17:00 (Europe/Amsterdam) | The Function Hall, Maastricht, 6229 EP, Netherlands
The REPO4EU Horizon Europe project to build a European/Global Platform for Drug Repurposing will kick off with the 1st International Conference on Drug Repurposing.
RExPO22 is the first instalment in the RExPO annual conference series and will take place in Maastricht, the Netherlands.
REPO4EU and RExPO22 have partnered with professional societies, companies, patent attorneys, legal and ethics experts, clinical research organisations, regulators, payers, patient representatives and many more! We have multiple collaborations around the world that pool together their knowledge and know-how to deliver the best possible outcome in the single major opportunity in drug development, i.e drug repurposing.
The speakers include Anton Ussi, EATRIS Operations and Finance Director, who will also co-chair the conference.
Find out more and see the agenda here. Abstract submission is still open here.
